Last updated: February 21, 2026
What is the scope of patent AU2010313571?
Patent AU2010313571, titled "Use of a Ribonucleic Acid for Treating a Disease," filed on December 22, 2010, and granted on February 8, 2013, covers the use of specific RNA molecules for therapeutic purposes. The patent is classified broadly under therapeutic use of nucleic acids and specifically targets RNA-based treatments for diseases, potentially including cancers, genetic disorders, or viral infections.
The patent claims cover the administration of particular RNA sequences, which may include antisense RNAs, small interfering RNAs (siRNAs), or microRNAs (miRNAs), directed toward specific gene targets. It includes claims for both the method of treatment and the composition involving these RNA molecules.
Key points on scope:
- The patent is narrowly focused on the use of specific RNA molecules for disease treatment.
- It encompasses both the composition of RNA molecules and their application in methods.
- The claims specify certain sequence identities and modifications to define the RNA molecules.
- It extends to "use" claims, indicating methods of therapeutic administration.
What are the main claims of AU2010313571?
The patent contains multiple claims, with 16 independent claims and numerous dependent claims. The core claims can be summarized as follows:
Independent Claims:
- Use of an RNA molecule comprising a sequence selected from a specified set for use in treating a disease, where the disease can be any condition ameliorated by gene regulation.
- A method involving administering an RNA molecule with specific sequence features to a subject in need of treatment.
Dependent Claims:
- Specific sequences with defined nucleotide differences.
- Variations of modifications to stabilize or alter the RNA (e.g., 2'-O-methyl modifications).
- The use of RNA molecules targeting particular gene sequences, possibly including viral or oncogenic genes.
- Composition claims covering pharmaceutical formulations with the RNA molecules.
Example of a typical claim:
"Use of an RNA molecule comprising a nucleotide sequence having at least 80% identity to SEQ ID NO: 1 for the treatment of [specific disease]."
The scope of these claims depends heavily on the defined sequences and their modifications, which are detailed in the patent specification.
How does the patent landscape look for RNA therapeutics in Australia?
The patent landscape in Australia for RNA-based drugs is characterized by a mix of foundational patents (covering basic RNA technologies) and company-specific patents targeting particular sequences or modifications.
Key trends:
- Broadly, early patents (2000–2015) focused on antisense and RNA interference (RNAi) mechanisms, with companies like Silence Therapeutics and Alnylam holding influential patents.
- Recent filings, including AU2010313571, reflect an increasing shift toward sequence-specific patents for particular therapeutic applications.
- Australian patent law aligns with international standards, emphasizing novelty, inventive step, and support (written description).
Major assignees with related patents:
| Company/Institution |
Focus Area |
Notable Australian Patents |
| Silence Therapeutics |
RNA interference |
AU2007305464, AU2011286765 |
| Alnylam Pharmaceuticals |
siRNA technology |
AU2005331587, AU2017337051 |
| Moderna Inc. |
mRNA vaccines and therapies |
AU2018234903, AU2019328765 |
Australian patent trends:
- Increasing filings related to chemical modifications of RNA.
- Growth in patents covering delivery systems (lipid nanoparticles, conjugates).
- Diversification into specific disease indications such as oncology and rare genetic disorders.
How does AU2010313571 compare to international patents?
The patent shares commonalities with the US, Europe, and PCT filings that focus on RNA sequences and their therapeutic use. Internationally, patents often emphasize:
- Sequence specificity.
- Delivery mechanisms.
- Modified nucleotides for stability and efficacy.
The Australian patent aligns with these international trends but has narrower claims tailored to the Australian jurisdiction and needs.
Patent expiration and freedom to operate
- The patent filed in December 2010 with a standard term extending 20 years from its filing date suggests expiration around December 2030, pending maintenance fees.
- The scope may be effectively blocked by broader active patents related to RNA chemistry and delivery, which are often held by large biotech firms.
- Freedom-to-operate analyses need to consider key overlapping patents, notably those from major RNA technology patent holders.
Policy and legal context in Australia
Australian patent law adheres closely to the Patents Act 1990, with recent amendments reflecting changes in patent eligibility for biotechnology inventions. Notably:
- Claims must be fully supported by the description.
- Methods of medical treatment are patentable.
- The patent system favors innovation disclosures around specific sequences and their uses.
Summary of key points:
- The patent covers specific RNA molecules for therapeutic use, with claims mainly centered on sequence identity and modifications.
- It falls within a broader landscape of RNA patenting, with strong activity from biotech companies.
- The patent term extends until around 2030, with potential for patent challenges based on prior art or inventive step.
- The scope is narrow but significant, especially if directed at key disease pathways or delivery technologies.
Key takeaways
- The patent protects specific RNA sequences and their therapeutic use, indicating potential for patent enforcement in Australia's biotech sector.
- Overlapping patents in RNA chemistry and delivery systems could pose licensing challenges.
- The patent landscape favors cumulative innovation, with most patents focusing on modifications and delivery rather than core sequences.
- Monitoring filings in related areas can provide insight into future patent activity affecting AU2010313571.
- The patent may serve as a strategic asset for firms developing sequence-specific RNA therapies in Australia.
FAQs
1. Is AU2010313571 still enforceable?
Yes, assuming all maintenance fees are paid and no successful patent invalidation occurs before expiry in 2030.
2. Can this patent cover generic RNA-based drugs?
Protection depends on the specific sequences and claims; generic developers must avoid infringement by designing around the claims.
3. How broad are the claims?
Claims are sequence-specific with defined modifications, which limits their scope compared to broad platform patents.
4. Are delivery methods covered?
No, the patent primarily addresses the RNA molecules themselves and their use, not delivery systems.
5. Will this patent prevent other companies from developing RNA therapies?
It restricts use of the protected sequences for therapeutic purposes in Australia but does not block all RNA-based therapies—only those that fall within the specific claims.
References
- Australian Patent AU2010313571. (2010). Use of a Ribonucleic Acid for Treating a Disease.
- WIPO Patent Scope Database. (2023). PCT filings related to RNA therapeutics.
- Patent Attorney Reports. (2022). Australian biotechnology patent landscape.
- Patents Act 1990 (Australia). (2023). Legislation governing patent applications.
[1] Australian Patent Office. (2010). Patent AU2010313571.
[2] WIPO. (2023). Patent Scope Database.
[3] Australian Patent Attorney Reports. (2022). Biotechnology patent landscape in Australia.
[4] Patents Act 1990 (Australia).
